| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA3891959
Max Phase: Preclinical
Molecular Formula: C21H41N3O2
Molecular Weight: 367.58
Molecule Type: Small molecule
Associated Items:
Representations
Canonical SMILES: CCCCCCCCCCCCCCCCNC(=O)C1(/C(N)=N/O)CC1
Standard InChI: InChI=1S/C21H41N3O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-18-23-20(25)21(16-17-21)19(22)24-26/h26H,2-18H2,1H3,(H2,22,24)(H,23,25)
Standard InChI Key: DZZUFBWUGQUZEI-UHFFFAOYSA-N
Associated Targets(Human)
Sphingosine kinase 1 1990 Activities
Associated Targets(non-human)
Sphingosine kinase 2 214 Activities
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 367.58 | Molecular Weight (Monoisotopic): 367.3199 | AlogP: 5.11 | #Rotatable Bonds: 17 |
| Polar Surface Area: 87.71 | Molecular Species: NEUTRAL | HBA: 3 | HBD: 3 |
| #RO5 Violations: 1 | HBA (Lipinski): 5 | HBD (Lipinski): 4 | #RO5 Violations (Lipinski): 1 |
| CX Acidic pKa: 9.92 | CX Basic pKa: 4.08 | CX LogP: 5.64 | CX LogD: 5.64 |
| Aromatic Rings: 0 | Heavy Atoms: 26 | QED Weighted: 0.11 | Np Likeness Score: -0.10 |
References
| 1. (2016) Imidamide sphingosine kinase inhibitors, |
Source
Source(1):